A probable case of linezolid-induced thrombocytopenia is reported.
Summary:
A 74-year-old Caucasian male with renal dysfunction was diagnosed with diverticulosis. Patient was prescribed linezolid 600 mg orally twice daily for vancomycin-resistant enterococci abdominal infection that developed secondary to colon resection. Upon initiation of linezolid, platelet count dropped from 248 000 cells/mm3 on day 1 to 97 000 cells/mm3 on day 5 of treatment. Linezolid was discontinued and platelet counts improved to pretreatment levels. Application of the Naranjo probability scale indicated a probable association of linezolid therapy and thrombocytopenia. Clinicians should be aware that linezolid has this hematologic side effect and that patients with renal dysfunction are at increased risk. Monitoring platelet count more than once weekly should be advisable in these patients.
Conclusion:
A 74-year-old Caucasian male with renal dysfunction developed a probable case of linezolid-induced thrombocytopenia after receiving the drug for 5 days for treatment of vancomycin-resistant enterococci abdominal infection.
GeorgeJNRaskobGEShahSRDrug-induced thrombocytopenia: a systematic reviewof published case reports. Ann Intern Med. 1998;129(11):886–890.
2.
SwisherKKLiXVeselySKDrug-induced thrombocytopenia: an updated systematic review. Drug Saf. 2009;32(1):85–86.
3.
AsterRBougieDW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–587.
4.
VisentinGPLiuCY. Drug induced thrombocytopenia. Hematol Oncol Clin North Am. 2007;21(4):685–696.
5.
AsterR. Drug-induced thrombocytopenia. In: MichelsonAD, ed. Platelets. New York, NY: Academic Press; 2007:887–902.
6.
Pfizer Inc. Zyvox (linezolid) Product Information. Pharmacia & Upjohn Company. Division of Pfizer Inc: New York, NY; 2010.
7.
PascoalinhoDVilasMJCoelhoLLinezolid-related immune-mediated severe thrombocytopenia. Int J Antimicrob Agents. 2011;37(1):88–89.
8.
GreenSLMaddoxJCHuttenbachED. Linezolid and reversible myelosuppression. JAMA. 2001;285(10):1291.
9.
WaldrepTWSkiestDJ. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy. 2002;22(1):109–112.
10.
LakhaniNThompsonWBombassaroAM. Probable linezolid-induced pancytopenia. Can J Infect Dis Med Microbiol. 2005;16(5):286–288.
11.
BernsteinWBTrottaRFRectorJTMechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517–520.
12.
KuterDJTillotsonGS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001;21(8):1010–1013.
13.
GersonSLKaplanSLBrussJBHematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–2726.
14.
MinsonQGentryCA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy. 2010;30(9):895–903.
15.
NiwaTSuzukiASakakibaraSRetrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–2133.
16.
OrrickJJJohnsTJanelleJThrombocytopenia secondary to linezolid administration: what is the risk?Clin Infect Dis. 2002;35(3):348–349.
17.
BishopEMelvaniSHowdenBPCharlesPGPGraysonML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50(4):1599–1602.
18.
AttassiKHershbergerEAlamRThrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5):695–698.
19.
RubinsteinEIsturizRStandifordHCWorldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47(6):1824–1831.
20.
NaranjoCABustoUSellersEMA method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
21.
SissonTLJungbluthGLHopkinsNK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793–797.
22.
BrierMEStalkerDJAronoffGRPharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775–2780.
23.
BonominiMSirolliV. Uremic toxicity and anemia. J Nephrol. 2003;16(1):21–28.
24.
StewartJH. Platelet numbers and life span in acute and chronic renal failure. Thromb Diath Haemorrh. 1967;17(3-4):532–542.
25.
LinYHWuVCTsaiIJHigh frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345–351.
26.
MatsumotoKTakedaYTakeshitaARenal function as a predictor of linezolid induced thrombocytopenia. Int J Antimicrob Agents. 2009;33(1):98–99.
27.
WuVCWangYTWangCYHigh frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72.
28.
RaoNHamiltonCW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007;59(2):173–179.
29.
SorianoAOrtegaMGarciaSComparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother. 2007;51(7):2559–2563.
30.
ZhanelGGShroederCVercaigneLA critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins. Can J Infect Dis. 2001;12(6):379–390.
31.
StalkerDJJungbluthGL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42(13):1129–1140.
